Insulin-like growth factor-I (IGF-I) stimulates mitogenesis in proliferating preadipocytes
INTRODUCTION
It is well established that insulin-like growth factor-I (IGF-I) plays an important role in preadipocyte growth and differentiation. IGF-I stimulates mitogenesis in many cell types in culture, including preadipocytes (1), and IGF-I (or pharmacological doses of insulin) is clearly required for preadipocyte differentiation in vitro (2, 3) . This dual role of IGF-I, stimulation of both mitogenesis and differentiation, indicates that these responses are not necessarily mutually exclusive. In vitro, IGF-I stimulates differentiation of preadipocytes once density-induced growth arrest has occurred (4) .
The mechanisms of intracellular signaling used by IGF-I to promote mitogenesis or differentiation of preadipocytes are now beginning to be elucidated. The biological effects of IGF-I are mediated through the IGF-I receptor (IGFR), a member of the tyrosine kinase family of growth factor receptors. The activated IGFR tyrosine kinase phosphorylates specific substrates, such as the adaptor proteins Shc and insulin receptor substrate-1 (IRS-1). Tyrosine phosphorylation of these proteins stimulates specific proteinprotein interactions via well characterized domains to mediate diverse signaling pathways (5) . Shc, a substrate for many growth factor receptor tyrosine kinases, is a key component of signaling complexes that activate several effector pathways, including the small G-protein Ras (6) . Ras then activates the three-kinase cascade terminating in the mitogen-activated protein kinases (MAPKs), extracellular signal regulated kinase 1 (ERK1) and ERK2 (7, 8) . These MAPK isoforms mediate the mitogenic effects of IGF-I in a number of cell types (9) (10) (11) . IRS-1, considered to be the major substrate of the IGFR, can activate multiple downstream targets, including Ras and phosphatidylinositol 3-kinase (PI3K) (5, 12) .
We have previously shown that IGF-I is a potent stimulator of the MAPKs ERK1 and ERK2 in proliferating 3T3-L1 preadipocytes, and that there is a dramatic decrease in IGF-I-stimulated MAPK activity during early differentiation of 3T3-L1 cells (13) . This change in MAPK signaling coincides with the loss of IGF-I-stimulated Shc, but not IRS-1, phosphorylation. This indicates that proximal signaling through Shc to MAPK is down-regulated very early in IGF-I-mediated preadipocyte differentiation. Activation of MAPK in growth-arrested 3T3-L1 cells through transfection of active components of the MAPK cascade (14) or by epidermal growth factor (15, 16) inhibits differentiation. Therefore, down-regulation of MAPK activity may be necessary for preadipocyte differentiation.
We hypothesized that down-regulation of MAPK via loss of proximal signaling by Shc is involved in mediating the IGF-I switch from 3T3-L1 mitogenesis to differentiation. We used a synthetic inhibitor of MAPK activation (PD098059) or a dominant-negative form of Shc to inhibit mitogenesis and promote differentiation in 3T3-L1 cells independently of the usual requirement for densityinduced growth arrest. PD098059 inhibits high-dose insulin stimulation of MAPK in 3T3-L1 cells (14) . The Shc mutant consists of a tyrosine-to-phenylalanine substitution at position 317, rendering it defective in signaling to Ras (17) . Our results demonstrate the critical role of Shc in the switch from IGF-I-mediated mitogenesis to IGF-Imediated differentiation of 3T3-L1 cells.
RESULTS

The Effect of the MAPK Inhibitor PD098059 on IGF-I-Stimulated Mitogenesis in 3T3-L1 Preadipocytes
To test whether MAPK mediates the mitogenic effects of IGF-I in proliferating 3T3-L1 preadipocytes, we asked whether PD098059, a specific noncompetitive inhibitor of the MAPK kinase, MEK-1 (18), would affect IGF-Istimulated MAPK activation and 3 H-thymidine incorporation. We treated subconfluent 3T3-L1 cells with or without 50 M PD098059 before stimulation with 10 nM IGF-I and then analyzed for active ERK-1 and -2 MAPK by Western blotting with phosphospecific MAPK antibodies. As expected, PD098059 was a potent inhibitor of IGF-I-stimulated MAPK activity in 3T3-L1 preadipocytes (Fig. 1A ).
We then measured 3 H-thymidine incorporation in IGF-I-stimulated cells in the presence and absence of 50 M PD098059 (Fig. 1B) . Treatment of proliferating cells with the MEK inhibitor substantially reduced 3 H-thymidine incorporation in response to IGF-I. DNA synthesis was negligible in postconfluent cells undergoing density-induced growth arrest. To make sure that inhibition of 3 H-thymidine incorporation by PD098059 reflected inhibition of proliferation and not an increase in cell death, cell cycle analysis was performed by standard flow cytometry. The percent apoptotic cells in asynchronous, proliferating cells was 1.26 ϩ 1.13 (mean ϩ SD; n ϭ 3), and the percent after overnight treatment with PD098059 was 0.74 ϩ 0.5 (mean ϩ SD; n ϭ 3).
The Effect of PD098059 on IGF-I-Stimulated Differentiation in Subconfluent 3T3-L1 Preadipocytes
To test the hypothesis that loss of MAPK activation is permissive for IGF-I-mediated differentiation, we treated A, 3T3-L1 cells (60-80% confluent) were treated with 10 nM IGF-I for 5 min after preincubation of cells for 2 h with or without 50 M PD098059. Cell lysates were resolved by SDS-PAGE and then analyzed by Western blotting for phosphorylated MAPK (P-MAPK) and total MAPK. This blot is representative of more than 10 repeats. B, Subconfluent, proliferating cells were serum starved overnight and treated with 10 nM IGF-I for 24 h. During the last 6 h, 3 H-thymidine (1 Ci per well) was added to proliferating cells in the absence (P) or presence (P/PD) of 50 M PD098059 or to growtharrested cells (GA). Incorporation of 3 H-thymidine into DNA is expressed as the mean and SEM (n ϭ 6 wells per condition). Similar results were seen in a second experiment. subconfluent 3T3-L1 preadipocytes with differentiationinducing medium (DMI) in the absence or presence of PD098059. Expression of differentiation-specific genes was determined by Northern analysis and RT-PCR. Northern analysis of total RNA for the lipid-binding protein adipocyte protein-2 (aP-2), a late marker of adipocyte differentiation, revealed detectable expression after treatment with DMI but enhanced expression in the presence of PD098059 (Fig. 2) . We then examined earlier markers of differentiation, peroxisome proliferator-activated receptor ␥ (PPAR␥), and lipoprotein lipase (LPL), using semiquantitative RT-PCR. Subconfluent preadipocytes were treated with DMI or serum-containing medium in the absence or presence of PD098059. PD098059 led to a modest enhancement in the expression of PPAR␥ in this and other repeat experiments. However, LPL was only detected in total RNA from cells treated with both PD098059 and DMI (Fig. 3) . These data suggest that inhibition of MAPK in subconfluent, proliferating 3T3-L1 cells accelerates differentiation.
Changes in IGF-I-Mitogenic Signaling in 3T3-L1 Preadipocytes Associated with Transfection of a Dominant-Negative Shc Mutant
Although IRS-1 is considered to be of primary importance in IGF-I signaling, both Shc and IRS-1 become phosphorylated when the IGF-I receptor is activated. To test the hypothesis that Shc is necessary for IGF-I mitogenic signaling in proliferating 3T3-L1 cells, we transiently transfected subconfluent cells with a dominant-negative Shc mutant. This mutant is a glutathione-S-transferase (GST) fusion protein with phenylalanine substituted for tyrosine at the 317 position of Shc, rendering it defective in signaling to Ras (17) . Expression of the mutant GST-ShcY317F is abundant by 24 h, reaches a maximum at 48 h and remains close to maximum at 72 h (data not shown). Figure 4A demonstrates maximal expression 48 h after transfection of the mutant GST-ShcY317F protein in comparison to the three endogenous isoforms of Shc. Western blot analysis of MAPK activation in proliferating cells 48 h after transfection revealed inhibition of IGF-I-stimulated MAPK activity by ShcY317F compared with empty vector (GST alone) or GST-wild-type Shc at transfection efficiencies of 40-50% (Fig. 4B) .
To test the effect of the dominant-negative Shc mutant on IGF-I-stimulated mitogenesis, we evaluated DNA synthesis by measuring BrdU incorporation in cells transfected with the GST-wild-type Shc or GSTShcY317F mutant and then treated with IGF-I. Using double fluorescent immunohistochemical staining for BrdU and GST, we counted the number of BrdUpositive nuclei in GST-positive cells. Immunohistochemical staining of BrdU and GST in a representative field of cells transfected with wild type Shc or the Shc mutant is shown in Fig. 5 . Cells expressing GST-wildtype Shc and exposed to BrdU have yellow nuclei and red cytoplasm (Fig. 5B) , indicating BrdU incorporation into cells transfected with wild-type Shc. However, staining of GST-ShcY317F-transfected cells revealed red cytoplasm but no nuclear BrdU staining (Fig. 5D ), indicating inhibition of BrdU uptake in cells expressing the Shc mutant. Also in this field is a nontransfected cell that is BrdU positive. In an experiment with 50-60% transfection efficiency, 100 cells were counted for each condition: 28% of cells transfected with the GST-ShcY317F mutant incorporated BrdU in response to IGF-I compared with 69% in cells transfected with GST-wild-type Shc (significance by Fischer's exact test gave a two-sided P ϭ 0.0001). These data demonstrate inhibition of IGF-I-stimulated DNA synthesis by the dominant-negative Shc in proliferating 3T3-L1 cells.
The Effect of the Dominant-Negative Shc Mutant on IGF-I-Stimulated Differentiation in Subconfluent 3T3-L1 Cells
Although mitogenesis and differentiation are considered to be mutually exclusive, IGF-I is known to stimulate both mitogenesis and differentiation in 3T3-L1 preadipocytes. We hypothesized that loss of mitogenic signaling through Shc is a key event in the switch from IGF-I-mediated mitogenesis to differentiation. To test this, we inhibited Shc signaling in subconfluent 3T3-L1 cells via transfection with dominantnegative Shc, and then treated cells 24 h after transfection with DMI and analyzed for early and late markers of adipocyte differentiation. Expression of the Forty eight hours after transfection of GST-wild-type Shc or GST-ShcY317F, cells were incubated with 10 M BrdU in the presence of 10 nM IGF-I for 4 h and then fixed in 100% cold methanol. Costaining of BrdU (yellow or green nuclei) and GST (red cytoplasm) followed by DAPI staining of nuclei was performed as described in Materials and Methods. Top panels, DAPI staining of nuclei (A) and costaining of BrdU and GST (B) in cells transfected with wild-type Shc. Bottom panels, DAPI staining of nuclei (C) and costaining of BrdU and GST (D) in cells transfected with ShcY317F. This experiment was repeated once with this antibody. However, two other repeat experiments also gave similar results, although specific staining was less dramatic using different primary antibodies for GST. late marker aP-2, assessed by Northern analysis of total RNA, was evident after 72 h of DMI treatment in cells transfected with Shc mutant (Fig. 6) . To examine earlier markers of differentiation, expression of PPAR␥ and LPL was evaluated by RT-PCR. After 60 h of treatment with DMI, cells transfected with dominantnegative Shc, but not empty vector (GST alone) or GST-wild type Shc, expressed significant PPAR␥ (Fig.  7A) . By 78 h, both the Shc mutant and empty vector transfectants expressed PPAR␥ (data not shown), but only cells transfected with the Shc mutant expressed LPL (Fig. 7B) . These data suggest that inhibition of Shc signaling is sufficient to permit differentiation in subconfluent 3T3-L1 cells.
DISCUSSION
It is well established that the MAPK signaling cascade mediates the mitogenic effects of IGF-I in numerous mesenchymal-derived cell systems, including myoblasts (19, 20) , rat-1 fibroblasts (21), vascular smooth muscle cells (22) , and rat fetal brown adipocytes (23) . As expected, we were able to demonstrate that the MEK-1 inhibitor PD098059 completely inhibits MAPK activation by IGF-I in subconfluent 3T3-L1 preadipocytes. By blocking IGF-I-stimulated MAPK activation, DNA synthesis is substantially reduced in subconfluent cells, indicating that the MAPK pathway is important for IGF-I-stimulated mitogenesis in 3T3-L1 preadipocytes.
Inhibition of MAPK by PD098059 promotes differentiation in subconfluent as well as growth-arrested 3T3-L1 cells. Compared with treatment with DMI alone, PD098059 increased expression of PPAR␥ and significantly increased expression of the later markers, suggesting that inhibition of MAPK activation is permissive for IGF-I-stimulated differentiation. Similar data were shown by Font de Mora et al. (14) using pharmacological doses of insulin in postconfluent cells. They demonstrated PD098059 inhibition of MAPK activation by insulin in 3T3-L1 cells and a small increase in differentiation markers in PD098059-treated growth-arrested cells. However, we have previously shown that MAPK activation by IGF-I in growth-arrested 3T3-L1 preadipocytes is already decreased (13), so we would predict the effect of PD098059 to be attenuated in growth-arrested compared with subconfluent cells.
Our results show that inhibition of MAPK, even in the absence of density-induced growth arrest, permits differentiation of 3T3-L1 cells. Similar observations have been made in IGF-I-mediated growth and differentiation of rat fetal brown adipocytes (23) and L6A1 myoblasts (24) . Those studies demonstrated the role of MAPK activation in mitogenesis and the promotion of differentiation by MAPK inhibition using PD098059, leading us to conclude that these signaling mechanisms may be common to cell systems in which IGF-I stimulates both proliferation and differentiation. In addition, mitogenic hormones such as epidermal growth factor and tumor necrosis factor ␣ (15, 16), as well as transfection of constitutively active components of the MAPK cascade, inhibit 3T3-L1 differentiation by activation of MAPK (14) . We conclude that loss of MAPK activation is both permissive and necessary for 3T3-L1 differentiation.
Several elegant studies by others have investigated the role of upstream mediators of MAPK in 3T3-L1 differentiation, including Raf-1 and Ras (25, 26) . Although these data indicate a role for Ras, and to a lesser extent Raf-1, in IGF-I-mediated 3T3-L1 differentiation, these signaling molecules activate MAPK in proliferating, but not differentiating, cells (27, 28) . Further upstream, signaling complexes are formed from activated adaptor proteins such as Shc or IRS-1, which can then bind Grb2 and Sos (5). These signaling complexes activate the small G protein Ras, which leads to Raf-1 activation. Raf-1 is the first kinase in the three-kinase cascade ending in MAPK (7, 8) .
We have previously shown that loss of MAPK activation by IGF-I in differentiating cells is associated with loss of Shc but not IRS-1 tyrosine phosphorylation (13) . We have now presented evidence suggesting that Shc is a critical upstream mediator of MAPK activation in IGF-I-mediated 3T3-L1 mitogenesis. We did so by transiently expressing a dominant-negative Shc that is defective in signaling to Ras. This ShcY317F mutant blocked IGF-I activation of MAPK, inhibited IGF-I-stimulated BrdU incorporation, and promoted differentiation in subconfluent 3T3-L1 cells. We found no inhibition of IRS-1 tyrosine phosphorylation and associated binding of the p85 subunit of PI3K in cells transfected with empty vector (GST alone), wild-type Shc, or ShcY317F (data not shown). Studies by Ishihara et al. (29) found inhibition of IRS-1 signaling in stably transfected Rat1 fibroblasts expressing insulin and not IGF-I receptors, GST-wild-type Shc and GSTShcY317F. However, unlike our experiments, expression of the GST-Shc proteins (wild-type and Y317F mutant) was in 10-fold excess of endogenous Shc, suggesting to us that inhibition of insulin-stimulated IRS-1 signaling may have been partly a result of the stoichiometry of the transfected proteins. Although we cannot absolutely rule out a role for IRS-1 in IGF-I mitogenic signaling, our results indicate a crucial role for Shc. Shc proteins have been shown to mediate the mitogenic effects of IGF-I in a number of other cell culture systems, including human neuroblastoma cells (30) , myeloid progenitor cells (31) , and rat-1 fibroblasts (32) . On the other hand, IRS-1 (33) and its downstream targets PI3K (34-36) and protein kinase B (37, 38) appear to have major roles in mediating the differentiating effects of IGF-I in 3T3-L1 cells as well as fetal rat brown adipocytes.
We interpret our present and prior results to suggest that a change in IGF-I signaling from Shc-mediated mitogenesis to IRS-1-mediated differentiation is central to the process of adipogenesis. Our results indicate that inhibiting mitogenesis in subconfluent cells by inhibition of MAPK or transient transfection of the ShcY317F mutant is permissive for differentiation. Relevant to all these potential mechanisms is the conclusion that Shc represents a crucial point of divergence between IGF-I-mediated mitogenesis and IGF-I-stimulated differentiation of 3T3-L1 cells.
MATERIALS AND METHODS
Materials
Tissue culture reagents, some RT-PCR reagents, plasmid pGreen lantern, and custom primers were purchased from Life Technologies, Inc. (Gaithersburg, MD). AdvanTaq Plus PCR kit and mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control primers were purchased from CLONTECH Laboratories, Inc. (Palo Alto, CA). Dexamethasone, methylisobutylxanthine, buffer reagents, and X-Omat AR film (Eastman Kodak, Rochester, NY) were purchased from Sigma (St. Louis, MO).
3 H-thymidine, 32 P-dCTP, enhanced chemiluminescence reagents, Hyperfilm ECL, and Hybond C nitrocellulose were purchased from Amersham Pharmacia Biotech (Arlington Heights, IL). Rabbit anti-Shc, rabbit anti-MAPK-1/2 (ERK1/2-CT), and rabbit anti-GST antibodies were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). Secondary antibodies for immunocytochemistry were purchased from Pierce Chemical Co. 
Cell Culture and Transfection
The murine preadipocyte line 3T3-L1 was obtained from American Type Culture Collection (Manassas, VA). Cells were grown in DMEM with l-glutamine, 1 g/liter glucose, 50 g/ml penicillin, 100 g/ml streptomycin, 0.25 g/ml Amphotericin, (Life Technologies, Inc., Gaithersburg, MD) and 10% FBS. Cultures were maintained in an atmosphere of 5% CO 2 -95% humidified air at 37 C. Serum-containing medium (SCM) was replaced every 3 days. Differentiation-inducing medium consisted of 0.5 M dexamethasone, 0.5 mM methylisobutylxanthine, and 7 nM IGF-I (DMI) in SCM.
For transient transfection of 3T3-L1 cells, cells were seeded in six-well plates. The plasmids provided included ShcY317F cloned into pEBG as a GST fusion protein, wildtype Shc cloned into pEBG as a GST fusion protein, and the pEBG vector containing only GST (empty vector). The mutant Shc, wild-type Shc, or the empty vector was transfected into 50% confluent cells with pGreen Lantern at a ratio of 10:1. The plasmid pGreen Lantern expresses green fluorescent protein and was used as a marker of transfection efficiency. Initially the reagent Lipofectin (Life Technologies, Inc.) was used with transfection efficiencies of 20-30%. Improved transfection was subsequently obtained using GenePorter (Gene Therapy Systems, San Diego, CA) with transfection efficiencies of 40-50%. Cells were used for experiments 24-48 h after transfection.
Evaluation of Apoptosis by Flow Cytometry
3T3-L1 cells were grown to 50-60% confluency in 10-cm 2 dishes. After overnight incubation in either SCM or SCM containing 50 M PD098059, cells were detached with 0.05% trypsin and 0.5 mM EDTA, resuspended in SCM, and washed once with PBS. The cells were resuspended in PBS and stained with 0.02% propidium iodide (Sigma) for 5-10 min. DNA content was analyzed on a FACSort (Becton Dickinson and Co. Immunocytometry Systems, San Jose, CA) equipped with an argon-ion laser at 488 nm and Modifit LT software (Verity Software House, Inc., Topsham, ME).
Western Blotting
Preparation of cell lysates for Western blotting was as described previously (13) , using lysis buffer with 1% Triton X-100 for anti-Shc Western blots and 0.2% Triton X-100 for anti-phospho-MAPK Western blots. Proteins were resolved by SDS-PAGE on 10% acrylamide gels and transferred to nitrocellulose. Membranes were blocked in 5% BSA in Trisbuffered saline with 0.1% Triton X-100 and probed with primary antibody at 1 g/ml. Specific binding was visualized using enhanced chemiluminescence and Hyperfilm ECL and then analyzed by digital image analysis using a ScanJet 6100C/T scanner (Hewlett-Packard Co., Palo Alto, CA).
RNA Preparation And Northern Blot Analysis
Total RNA was prepared using Tri Reagent (Molecular Research Center, Inc., Cincinnati, OH). Aliquots of total RNA were denatured with dimethylsulfoxide and glyoxal, fractionated by agarose gel electrophoresis and transferred to GeneScreen nylon membranes (NEN Life Science Products, Boston, MA). Membranes were prehybridized in High Efficiency Hybridization solution without formamide (Molecular Research Center, Inc., Cincinnati, OH) and then hybridized with [␣-32 P]dCTP-radiolabeled cDNA for aP-2 using a random primed labeling kit (Roche Molecular Biochemicals, Indianapolis, IN). After extensive posthybridization rinses at 60 C, blots were exposed to X-Omat film (Eastman Kodak Co.).
Semiquantitative RT-PCR
Aliquots of 2 g total RNA were DNAse treated before reverse transcription and primer-dropping PCR as described previously (51) . Primer sequences used for detection of murine PPAR␥2 transcripts were taken from Vidal-Puig et al. (52) and resulted in a predicted PCR product of 277 bp. Primer sequences used for detection of murine LPL transcripts were, from 5Ј to 3Ј, left GCGTAGCAGGAAGTCTGACC, right CTA-CAACTCAGGCAGAGCCC and resulted in a predicted PCR product of 421 bp. Primers for murine GAPDH were purchased from CLONTECH Laboratories, Inc. and resulted in a predicted PCR product of 980 bp. Optimal PCR cycles required for linear amplification for each primer set were determined. Total amplification in each reaction (GAPDH plus PPAR␥2 or GAPDH plus LPL) was kept below saturation levels to permit the two products to remain within each primer set's exponential range. GAPDH required 16 to 20 cycles, and its expression was the same in proliferating, postconfluent or differentiating 3T3-L1 cells. PPAR␥2 required 22-26 cycles and LPL required 19-22 cycles, and these cycles were determined from differentiating 3T3-L1 cells. Gels were illuminated with UV light and photographed with Polaroid film.
H-Thymidine and Bromodeoxyuridine (BrdU) Incorporation
For 3 H-thymidine incorporation, cell monolayers were grown to approximately 70% confluence in six-well plates and serum-starved overnight in DMEM with 0.1% BSA before treatment with 10 nM IGF-I for 24 h. Cells were incubated with 50 M PD098059 (from a stock of 50 mM in DMSO) or an equal volume of DMSO in the presence of 1 Ci/well 3 H-thymidine for 6 h before lysis in 0.33 M NaOH. An aliquot was removed for protein assay before DNA precipitation with ice-cold 40% TCA/1.2 M HCl and collection on glass fiber filters for counting. The background level of 3 H-thymidine was less than 200 cpm as determined by the addition of 3 H-thymidine to a control well just before cell lysis and DNA precipitation.
BrdU incorporation was determined in cell monolayers transfected with wild-type Shc or ShcY317F at 50% confluency in six-well plates. Forty-eight hours after transfection, monolayers were placed in DMEM plus 0.1% BSA or DMEM plus 0.1% BSA and 10 nM IGF-I overnight followed by incubation with 10 M BrdU (BrdU labeling and detection kit II, Roche Molecular Biochemicals) for 4 h. The cell monolayers were fixed in 100% ice-cold methanol at Ϫ20 C for 10 min, allowed to air dry, and then stored at Ϫ20 C.
Immunocytochemistry
For immunocytochemical costaining of BrdU incorporation and GST expression, fixed cells were blocked in 1% normal goat serum before incubation with 1:15 dilution of mouse anti-BrdU (BrdU labeling and detection kit II, Roche Molecular Biochemicals) at 37 C for 60 min followed by 10 g/ml fluorescein isothiocyanate-conjugated goat antimouse IgG at room temperature for 30 min. The monolayers were washed with PBS, blocked in 1% normal donkey serum, and then blocked with avidin and biotin. Cells were incubated in 10 g/ml rabbit anti-GST in 1% normal donkey serum followed by 10 g/ml biotin-conjugated donkey anti-rabbit IgG and then Texas red streptavidin at a 1:200 dilution. All incubations were at room temperature for 30 min. Coverslips were mounted with Vectashield plus DAPI. Random fields of view were evaluated using an Eclipse 800 Photomicroscope (Nikon, Melville, NY) equipped with an epi-fluorescence condenser to analyze staining of BrdU in the nucleus and GST in the cytoplasm. Total number of cells was determined from DAPI staining of nuclei. Photomicrographs of monolayers were recorded using a Sensys digital camera connected to a power MacIntosh 8500 running IP Lab Spectrum P imaging software.
